RXRX
Recursion Pharmaceuticals Inc
4.10$
+2.5%
vs. previous close
Closing price · As of: Sep 30, 2026
Statements
Income Statement
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 107.7% | 93.0% | 82.8% | 63.9% | 46.3% | 283.6% | 148.0% | 105.5% | 571.8% | 75.6% | 193.0% | 149.8% | 146.7% | |
| -7.7% | 7.0% | 17.2% | 36.1% | 53.7% | -183.6% | -48.0% | -5.5% | -471.8% | 24.4% | -93.0% | -49.8% | -46.7% | |
| 693.0% | 654.0% | 500.8% | 513.2% | 286.0% | 2,179.9% | 879.2% | 673.4% | 2,339.4% | 234.5% | 1,358.1% | 1,168.4% | 696.2% | |
| 289.0% | 286.7% | 232.8% | 221.0% | 144.8% | 1,711.1% | 370.6% | 244.2% | 804.4% | 94.7% | 534.5% | 541.5% | 276.0% | |
| 977.8% | 938.2% | 731.3% | 734.2% | 430.8% | 3,890.2% | 1,249.8% | 917.0% | 2,855.7% | 329.2% | 1,892.6% | 1,709.9% | 945.1% | |
| -985.4% | -931.2% | -714.1% | -698.0% | -377.1% | -4,073.8% | -1,297.9% | -922.5% | -3,327.6% | -304.8% | -1,985.6% | -1,759.7% | -991.7% | |
| 0.2% | 0.2% | 0.1% | 2.7% | 2.1% | 13.4% | 3.4% | 2.5% | 16.1% | 0.0% | 5.4% | 4.0% | 2.7% | |
| -920.8% | -913.6% | -683.1% | -680.8% | -366.8% | -3,965.8% | -1,374.3% | -899.8% | -3,135.3% | -304.2% | -1,886.7% | -1,708.0% | -954.3% | |
| 15.9% | -38.2% | -5.8% | -3.6% | 0.6% | 0.2% | -1.1% | – | 0.1% | 0.1% | -71.1% | 0.0% | -8.4% | |
| -920.8% | -875.3% | -677.3% | -677.2% | -366.8% | -3,966.0% | -1,373.3% | -899.8% | -3,135.3% | -304.2% | -1,815.6% | -1,708.0% | -945.9% | |
| -845.5% | -842.2% | -628.2% | -615.8% | -337.1% | -3,665.3% | -1,239.8% | -772.5% | -2,728.6% | -249.4% | -1,577.3% | -1,467.1% | -810.2% |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: September 30, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.